Ramiprilum [Latin] en es it fr

Category

Ramiprilum_[Latin]
add to favotites goo dig stu tec squ mys
fac del pro twi yah mya far


Ramiprilum [Latin] Brand names, Ramiprilum [Latin] Analogs

Ramiprilum [Latin] Brand Names Mixture

  • No information avaliable

Ramiprilum [Latin] Chemical_Formula

C23H32N2O5

Ramiprilum [Latin] RX_link

http://www.rxlist.com/cgi/generic/ramipril.htm

Ramiprilum [Latin] fda sheet

Ramiprilum [Latin] msds (material safety sheet)

Ramiprilum_[Latin] MSDS

Ramiprilum [Latin] Synthesis Reference

E. H. Gold et al., U.S. Pat. 4,587,258 (1967).

Ramiprilum [Latin] Molecular Weight

416.511 g/mol

Ramiprilum [Latin] Melting Point

109 oC

Ramiprilum [Latin] H2O Solubility

3.5mg/L

Ramiprilum [Latin] State

Solid

Ramiprilum [Latin] LogP

3.149

Ramiprilum [Latin] Dosage Forms

Capsule

Ramiprilum [Latin] Indication

For diuretics and digitalis in congestive heart failure as adjunctive therapy and for use in prophylaxis in post MI.

Ramiprilum [Latin] Pharmacology

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor similar to benazepril, fosinopril, and quinapril. An inactive prodrug, ramipril is converted to ramiprilat in the liver and is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients.

Ramiprilum [Latin] Absorption

The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract, although the rate of absorption is reduced.

Ramiprilum [Latin] side effects and Toxicity

The most likely clinical manifestations would be symptoms attributable to hypotension. LD50 = 10933 mg/kg (orally in mice).

Ramiprilum [Latin] Patient Information

Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

Angioedema: Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors, especially following the first dose. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported. Patients should be told that if syncope occurs, ramipril should be discontinued until the physician has been consulted.

All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

Neutropenia: Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

Ramiprilum [Latin] Organisms Affected

Humans and other mammals